NASDAQ: GHGuardant Health Inc Stock
$44.97-0.21 (-0.46%)
Updated Apr 17, 2025
GH Price
$44.97
Fair Value Price
N/A
Market Cap
$5.55B
52 Week Low
$16.77
52 Week High
$50.89
P/E
-12.63x
P/B
-39.74x
P/S
5.07x
PEG
N/A
Dividend Yield
N/A
Revenue
$739.02M
Earnings
-$436.37M
Gross Margin
60.8%
Operating Margin
-58.52%
Profit Margin
-59%
Debt to Equity
-11.64
Operating Cash Flow
-$240M
Beta
1.57
Next Earnings
Jun 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
GH Overview
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GH's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
GH
Ranked#35 of 45
Ranked#35 of 45
Be the first to know about important GH news, forecast changes, insider trades & much more!
GH News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GH is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
GH's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more GH due diligence checks available for Premium users.
Valuation
GH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-12.63x
Industry
36.04x
Market
27.98x
GH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-39.74x
Industry
3.26x
GH's financial health
Profit margin
Revenue
$201.8M
Net Income
-$111.0M
Profit Margin
-55%
GH's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
GH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.5B
Liabilities
$1.6B
Debt to equity
-11.64
GH's short-term assets ($1.06B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GH's long-term liabilities ($1.40B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$64.5M
Investing
$10.5M
Financing
-$2.9M
GH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GH vs Diagnostic & Research Stocks
Guardant Health Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.